Compile Data Set for Download or QSAR
Report error Found 71 Enz. Inhib. hit(s) with all data for entry = 2888
TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384241BDBM384241(US10280184, Example F.1.4)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384242BDBM384242(US10280184, Example F.1.5)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384233BDBM384233(US10280184, Example E.1.6)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384232BDBM384232(US10280184, Example E.1.5)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384231BDBM384231(US10280184, Example E.1.4)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384230BDBM384230(US10280184, Example E.1.3)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384237BDBM384237(US10280184, Example E.1.10)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384236BDBM384236(US10280184, Example E.1.9)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384235BDBM384235(US10280184, Example E.1.8)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384234BDBM384234(US10280184, Example E.1.7)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384257BDBM384257(US10280184, Example F.1.22)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384246BDBM384246(US10280184, Example F.1.9)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384272BDBM384272(US10280184, Example F.1.38)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384269BDBM384269(US10280184, Example F1.35)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384276BDBM384276(US10280184, Example F.1.42)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384275BDBM384275(US10280184, Example F.1.41)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384274BDBM384274(US10280184, Example F.1.40)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384273BDBM384273(US10280184, Example F.1.39)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384261BDBM384261(US10280184, Example F1.26)
Affinity DataIC50: 100nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384224BDBM384224(US10280184, Example A.1.8)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384223BDBM384223(US10280184, Example A.1.7)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384222BDBM384222(US10280184, Example A.1.6)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384229BDBM384229(US10280184, Example E.1.2)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384228BDBM384228(US10280184, Example E.1.1)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384227BDBM384227(US10280184, Example D.1.2)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384226BDBM384226(US10280184, Example D.1.1)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384280BDBM384280(US10280184, Example G.1.4 | US10280184, Example G....)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384217BDBM384217(US10280184, Example A.1.1)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384279BDBM384279(US10280184, Example G.1.1)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384278BDBM384278(US10280184, Example F.1.44)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384277BDBM384277(US10280184, Example F.1.43)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384221BDBM384221(US10280184, Example A.1.5)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384220BDBM384220(US10280184, Example A.1.4)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384280BDBM384280(US10280184, Example G.1.4 | US10280184, Example G....)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384219BDBM384219(US10280184, Example A.1.3)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384281BDBM384281(US10280184, Example G.1.3)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 384218BDBM384218(US10280184, Example A.1.2)
Affinity DataIC50: 100nMAssay Description:The CSF-1R construct corresponds to recombinant human catalytic domain (aa 538-910), which was purchased from Invitrogen (cat #PV4092). CSF-1R was mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384239BDBM384239(US10280184, Example F.1.2)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384270BDBM384270(US10280184, Example F1.36)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384238BDBM384238(US10280184, Example F.1.1)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384245BDBM384245(US10280184, Example F.1.8)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384243BDBM384243(US10280184, Example F.1.6)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384264BDBM384264(US10280184, Example F1.30)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384263BDBM384263(US10280184, Example F1.29)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384262BDBM384262(US10280184, Example F.128)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384268BDBM384268(US10280184, Example F1.34)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384256BDBM384256(US10280184, Example F.1.21)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384255BDBM384255(US10280184, Example F.1.20)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384254BDBM384254(US10280184, Example F.1.19)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Abbvie

US Patent
LigandChemical structure of BindingDB Monomer ID 384286BDBM384286(US10280184, Example I.1.4)
Affinity DataIC50: 550nMAssay Description:The in-house BTK corresponds to recombinant human catalytic domain (aa 393-659), which was expressed in SF9 cells with an N-terminal his tag and puri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

Displayed 1 to 50 (of 71 total ) | Next | Last >>
Jump to: